Literature DB >> 15654028

Apomorphine in idiopathic restless legs syndrome: an exploratory study.

G G Tribl1, T Sycha, N Kotzailias, J Zeitlhofer, E Auff.   

Abstract

BACKGROUND: Dopaminergic and opioidergic drugs have been found to be effective in patients with restless legs syndrome (RLS).
OBJECTIVES: To test the effect of apomorphine--a combined opioidergic and dopaminergic agonist--and subsequent selective antagonism by naloxone and metoclopramide on subjective and objective symptoms in patients with idiopathic RLS.
METHODS: Nine patients with RLS were pretreated with oral domperidone for three days. A modified suggested immobilisation test (SIT) was carried out between 8 pm and 1 am under the following conditions of intravenous drug administration: baseline-apomorphine-apomorphine plus naloxone-apomorphine plus metoclopramide. Outcome variables were a visual analogue scale (VAS) of subjective RLS symptoms and EMG documented periodic leg movements while awake (PLMW).
RESULTS: Compared with baseline, apomorphine resulted in a rapid and significant improvement in subjective RLS symptoms as measured by VAS (54.5% improvement; p = 0.011), and an almost immediate cessation of PLMW, measured by PLMW index (98.0% improvement; p = 0.012). Neither additional naloxone nor metoclopramide blocked this effect significantly. While given apomorphine with metoclopramide, there was a trend to reappearance of PLMW.
CONCLUSIONS: Apomorphine may be an effective treatment for idiopathic RLS. Its effectiveness may reflect both to its dopaminergic and its opioidergic activity, and is not diminished significantly by blocking only one of these pathways. The trend to a worsening of the PLMW index with metoclopramide hints at a primarily dopaminergic effect of apomorphine in idiopathic RLS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654028      PMCID: PMC1739522          DOI: 10.1136/jnnp.2003.034843

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  47 in total

1.  Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients.

Authors: 
Journal:  Sleep Med       Date:  2001-01       Impact factor: 3.492

2.  Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.

Authors:  T Kraus; A Schuld; T Pollmächer
Journal:  J Clin Psychopharmacol       Date:  1999-10       Impact factor: 3.153

3.  Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

4.  Restless Legs Syndrome: scoring criteria for leg movements recorded during the suggested immobilization test.

Authors:  M Michaud; G Poirier; G Lavigne; J Montplaisir
Journal:  Sleep Med       Date:  2001-07       Impact factor: 3.492

5.  Epidemiology of restless legs symptoms in adults.

Authors:  B Phillips; T Young; L Finn; K Asher; W A Hening; C Purvis
Journal:  Arch Intern Med       Date:  2000-07-24

6.  Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.

Authors:  A J Hughes; S Bishop; B Kleedorfer; N Turjanski; W Fernandez; A J Lees; G M Stern
Journal:  Mov Disord       Date:  1993-04       Impact factor: 10.338

7.  Restless Legs Syndrome among working-aged women.

Authors:  J Ulfberg; B Nyström; N Carter; C Edling
Journal:  Eur Neurol       Date:  2001       Impact factor: 1.710

8.  Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.

Authors:  C Brodeur; J Montplaisir; R Godbout; R Marinier
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

9.  Restless legs syndrome probably induced by risperidone treatment.

Authors:  T C Wetter; J Brunner; T Bronisch
Journal:  Pharmacopsychiatry       Date:  2002-05       Impact factor: 5.788

10.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

View more
  4 in total

1.  Continuous Subcutaneous Apomorphine Infusion Improves Severe Restless Legs Syndrome.

Authors:  Thomas Müller; Marion Marg; Hartmut Rothe; Matthias Küchler
Journal:  Mov Disord Clin Pract       Date:  2014-06-04

Review 2.  Role of apomorphine in the treatment of Parkinson's disease.

Authors:  Allison Boyle; William Ondo
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

3.  Treatment of sleep disorders in elderly patients.

Authors:  John J Harrington; Alon Y Avidan
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.598

Review 4.  The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Drugs R D       Date:  2018-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.